tiprankstipranks
Trending News
More News >
Merus NV (MRUS)
:MRUS
US Market

Merus (MRUS) Stock Forecast & Price Target

Compare
458 Followers
See the Price Targets and Ratings of:

MRUS Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Merus
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRUS Stock 12 Month Forecast

Average Price Target

$94.70
▲(72.03%Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Merus in the last 3 months. The average price target is $94.70 with a high forecast of $110.00 and a low forecast of $67.00. The average price target represents a 72.03% change from the last price of $55.05.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"$38","111":"$111","56.25":"$56.3","74.5":"$74.5","92.75":"$92.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$94.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$67.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,56.25,74.5,92.75,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.53,62.48923076923077,66.44846153846154,70.40769230769232,74.36692307692307,78.32615384615384,82.28538461538461,86.24461538461539,90.20384615384616,94.16307692307691,98.12230769230769,102.08153846153846,106.04076923076923,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.53,61.31230769230769,64.09461538461538,66.87692307692308,69.65923076923077,72.44153846153847,75.22384615384615,78.00615384615385,80.78846153846155,83.57076923076923,86.35307692307693,89.13538461538462,91.9176923076923,{"y":94.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.53,59.181538461538466,59.83307692307692,60.48461538461539,61.136153846153846,61.78769230769231,62.43923076923077,63.09076923076923,63.74230769230769,64.39384615384616,65.04538461538462,65.69692307692307,66.34846153846154,{"y":67,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.24,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.45,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.42,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.99,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.05,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$110.00Average Price Target$94.70Lowest Price Target$67.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on MRUS
TipRanks AITipRanks
Not Ranked
TipRanks
$62
Hold
12.62%
Upside
Reiterated
06/05/25
Merus's stock score is bolstered by strong technical momentum and positive corporate events, including successful funding and clinical trials. Financial weaknesses, including persistent losses and cash flow issues, are significant risks. Valuation concerns due to a negative P/E ratio moderate the overall score.
Citi
$97$102
Buy
85.29%
Upside
Reiterated
06/11/25
Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS) and IGM Biosciences (NASDAQ: IGMS)
Bank of America Securities Analyst forecast on MRUS
Tazeen AhmadBank of America Securities
Bank of America Securities
$92
Buy
67.12%
Upside
Reiterated
06/10/25
Merus's Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target
LifeSci Capital Analyst forecast on MRUS
Charles ZhuLifeSci Capital
LifeSci Capital
$110
Buy
99.82%
Upside
Reiterated
06/09/25
Underappreciated Potential of Merus's Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability
Wells Fargo
$140$89
Buy
61.67%
Upside
Reiterated
06/03/25
Wells Fargo Sticks to Their Buy Rating for Merus (MRUS)
TD Cowen
Buy
Reiterated
06/03/25
TD Cowen Sticks to Its Buy Rating for Merus (MRUS)
Guggenheim Analyst forecast on MRUS
Michael SchmidtGuggenheim
Guggenheim
$111$109
Buy
98.00%
Upside
Reiterated
06/02/25
Merus (MRUS) Receives a Buy from Guggenheim
Truist Financial Analyst forecast on MRUS
Asthika GoonewardeneTruist Financial
Truist Financial
Buy
Reiterated
06/02/25
Truist Financial Keeps Their Buy Rating on Merus (MRUS)
H.C. Wainwright Analyst forecast on MRUS
Andres Y. MaldonadoH.C. Wainwright
H.C. Wainwright
$85
Buy
54.41%
Upside
Reiterated
05/27/25
H.C. Wainwright Sticks to Their Buy Rating for Merus (MRUS)
Leerink Partners Analyst forecast on MRUS
Andrew BerensLeerink Partners
Leerink Partners
$88$95
Buy
72.57%
Upside
Reiterated
05/27/25
Merus (MRUS) Gets a Buy from Leerink Partners
BMO Capital Analyst forecast on MRUS
Evan SeigermanBMO Capital
BMO Capital
$96$110
Buy
99.82%
Upside
Reiterated
05/23/25
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Merus (NASDAQ: MRUS) and Exelixis (NASDAQ: EXEL)
Needham Analyst forecast on MRUS
Ami FadiaNeedham
Needham
$75$88
Buy
59.85%
Upside
Reiterated
05/23/25
Merus's Peto+Pembro Shows Promising Potential in HNSCC with High Survival Rates and Increased Price Target
Canaccord Genuity Analyst forecast on MRUS
John NewmanCanaccord Genuity
Canaccord Genuity
$67
Buy
21.71%
Upside
Reiterated
05/23/25
Promising Developments in Cancer Treatment Drive Buy Rating for Merus with $67 Price Target
William Blair Analyst forecast on MRUS
Matt PhippsWilliam Blair
William Blair
Buy
Reiterated
05/23/25
Merus's Promising Oncology Advancements Justify Buy Rating Amidst Strong Clinical Results
Stifel Nicolaus Analyst forecast on MRUS
Bradley CaninoStifel Nicolaus
Stifel Nicolaus
$93
Buy
68.94%
Upside
Reiterated
03/06/25
Stifel Nicolaus Sticks to Its Buy Rating for Merus (MRUS)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on MRUS
TipRanks AITipRanks
Not Ranked
TipRanks
$62
Hold
12.62%
Upside
Reiterated
06/05/25
Merus's stock score is bolstered by strong technical momentum and positive corporate events, including successful funding and clinical trials. Financial weaknesses, including persistent losses and cash flow issues, are significant risks. Valuation concerns due to a negative P/E ratio moderate the overall score.
Citi
$97$102
Buy
85.29%
Upside
Reiterated
06/11/25
Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS) and IGM Biosciences (NASDAQ: IGMS)
Bank of America Securities Analyst forecast on MRUS
Tazeen AhmadBank of America Securities
Bank of America Securities
$92
Buy
67.12%
Upside
Reiterated
06/10/25
Merus's Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target
LifeSci Capital Analyst forecast on MRUS
Charles ZhuLifeSci Capital
LifeSci Capital
$110
Buy
99.82%
Upside
Reiterated
06/09/25
Underappreciated Potential of Merus's Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability
Wells Fargo
$140$89
Buy
61.67%
Upside
Reiterated
06/03/25
Wells Fargo Sticks to Their Buy Rating for Merus (MRUS)
TD Cowen
Buy
Reiterated
06/03/25
TD Cowen Sticks to Its Buy Rating for Merus (MRUS)
Guggenheim Analyst forecast on MRUS
Michael SchmidtGuggenheim
Guggenheim
$111$109
Buy
98.00%
Upside
Reiterated
06/02/25
Merus (MRUS) Receives a Buy from Guggenheim
Truist Financial Analyst forecast on MRUS
Asthika GoonewardeneTruist Financial
Truist Financial
Buy
Reiterated
06/02/25
Truist Financial Keeps Their Buy Rating on Merus (MRUS)
H.C. Wainwright Analyst forecast on MRUS
Andres Y. MaldonadoH.C. Wainwright
H.C. Wainwright
$85
Buy
54.41%
Upside
Reiterated
05/27/25
H.C. Wainwright Sticks to Their Buy Rating for Merus (MRUS)
Leerink Partners Analyst forecast on MRUS
Andrew BerensLeerink Partners
Leerink Partners
$88$95
Buy
72.57%
Upside
Reiterated
05/27/25
Merus (MRUS) Gets a Buy from Leerink Partners
BMO Capital Analyst forecast on MRUS
Evan SeigermanBMO Capital
BMO Capital
$96$110
Buy
99.82%
Upside
Reiterated
05/23/25
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Merus (NASDAQ: MRUS) and Exelixis (NASDAQ: EXEL)
Needham Analyst forecast on MRUS
Ami FadiaNeedham
Needham
$75$88
Buy
59.85%
Upside
Reiterated
05/23/25
Merus's Peto+Pembro Shows Promising Potential in HNSCC with High Survival Rates and Increased Price Target
Canaccord Genuity Analyst forecast on MRUS
John NewmanCanaccord Genuity
Canaccord Genuity
$67
Buy
21.71%
Upside
Reiterated
05/23/25
Promising Developments in Cancer Treatment Drive Buy Rating for Merus with $67 Price Target
William Blair Analyst forecast on MRUS
Matt PhippsWilliam Blair
William Blair
Buy
Reiterated
05/23/25
Merus's Promising Oncology Advancements Justify Buy Rating Amidst Strong Clinical Results
Stifel Nicolaus Analyst forecast on MRUS
Bradley CaninoStifel Nicolaus
Stifel Nicolaus
$93
Buy
68.94%
Upside
Reiterated
03/06/25
Stifel Nicolaus Sticks to Its Buy Rating for Merus (MRUS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merus

1 Month
xxx
Success Rate
10/18 ratings generated profit
56%
Average Return
+1.49%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +1.49% per trade.
3 Months
xxx
Success Rate
10/13 ratings generated profit
77%
Average Return
+19.46%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +19.46% per trade.
1 Year
Charles ZhuLifeSci Capital
Success Rate
15/18 ratings generated profit
83%
Average Return
+30.38%
reiterated a buy rating 4 days ago
Copying Charles Zhu's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +30.38% per trade.
2 Years
xxx
Success Rate
26/27 ratings generated profit
96%
Average Return
+86.19%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 96.30% of your transactions generating a profit, with an average return of +86.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRUS Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
27
20
22
28
28
Buy
12
5
7
14
17
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
25
29
42
45
In the current month, MRUS has received 45 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MRUS average Analyst price target in the past 3 months is 94.70.
Each month's total comprises the sum of three months' worth of ratings.

MRUS Financial Forecast

MRUS Earnings Forecast

Next quarter’s earnings estimate for MRUS is -$1.16 with a range of -$1.49 to -$0.93. The previous quarter’s EPS was -$1.40. MRUS beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year MRUS has Outperformed its overall industry.
Next quarter’s earnings estimate for MRUS is -$1.16 with a range of -$1.49 to -$0.93. The previous quarter’s EPS was -$1.40. MRUS beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year MRUS has Outperformed its overall industry.

MRUS Sales Forecast

Next quarter’s sales forecast for MRUS is $10.45M with a range of $2.97M to $26.80M. The previous quarter’s sales results were $26.49M. MRUS beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year MRUS has Outperformed its overall industry.
Next quarter’s sales forecast for MRUS is $10.45M with a range of $2.97M to $26.80M. The previous quarter’s sales results were $26.49M. MRUS beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year MRUS has Outperformed its overall industry.

MRUS Stock Forecast FAQ

What is MRUS’s average 12-month price target, according to analysts?
Based on analyst ratings, Merus NV’s 12-month average price target is 94.70.
    What is MRUS’s upside potential, based on the analysts’ average price target?
    Merus NV has 72.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MRUS a Buy, Sell or Hold?
          Merus NV has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Merus NV’s price target?
            The average price target for Merus NV is 94.70. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $110.00 ,the lowest forecast is $67.00. The average price target represents 72.03% Increase from the current price of $55.05.
              What do analysts say about Merus NV?
              Merus NV’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of MRUS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis